舒肝解郁胶囊联合文拉法辛治疗抑郁症临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R749.4

基金项目:


Clinical Study on Shugan Jieyu Capsules Combined with Venlafaxine for Depression
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察舒肝解郁胶囊联合文拉法辛治疗抑郁症的临床疗效。方法:选取300 例抑郁症患者,随机分为治疗组和对照组,每组150 例。对照组给予文拉法辛治疗,治疗组在对照组基础上加服舒肝解郁胶囊治疗,2 组均治疗8 周。比较2 组临床疗效及不良反应;比较2 组治疗前后血清炎性因子及神经递质水平。结果:治疗组总有效率为94.00%,高于对照组的87.33%(P<0.05)。治疗后,2 组血清超敏C-反应蛋白(hs-CRP)、白细胞介素-2(IL-2) 及肿瘤坏死因子-α(TNF-α) 水平均较治疗前降低(P<0.05),治疗组血清hs-CRP、IL-2、TNF-α 水平均低于对照组(P<0.05);2 组血清多巴胺(DA)、去甲肾上腺素(NE)、5-羟色胺(5-HT) 水平均较治疗前升高(P<0.05),治疗组血清DA、NE、5-HT 水平均高于对照组(P<0.05)。治疗组不良反应发生率为8.67%,对照组不良反应发生率为6.67%,2 组比较,差异无统计学意义(P>0.05)。结论:舒肝解郁胶囊联合文拉法辛治疗抑郁症能够提高临床疗效,作用机制可能与调节炎性因子及神经递质水平有关。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Shugan Jieyu capsules combined with venlafaxine for depression. Methods:A total of 300 cases of patients with depression were selected and randomly divided into the control group and the treatment group, 150 cases in each group. The control group was given venlafaxine, and the treatment group was additionally treated with Shugan Jieyu capsules based on the treatment of the control group. Both groups were treated for eight weeks. The clinical effect and adverse reactions were compared between the two groups. Before and after treatment, levels of inflammatory factors and neurotransmitters in serum were compared between the two groups. Results:The total effective rate was 94.00% in the treatment group,higher than that of 87.33% in the control group(P<0.05). After treatment, levels of high-sensitivity C-reactive protein(hs-CRP),interleukin-2(IL-2) and tumor necrosis factor- α(TNF- α) in serum in the two groups were decreased when compared with those before treatment(P<0.05), and the three levels above in the treatment group were lower than those in the control group(P<0.05). After treatment, levels of dopamine(DA), norepinephrine(NE),and 5-hydroxytryptamine(5-HT) in serum in the two groups were increased when compared with those before treatment(P<0.05),and the three levels above in the treatment group were higher than those in the control group(P< 0.05). The incidence of adverse reactions was 8.67% in the treatment group,and 6.67% in the control group,no significance being found in the difference(P>0.05). Conclusion: The therapy of Shugan Jieyu capsules combined with venlafaxine for depression can effectively improve clinical effect, whose mechanism maybe related to the regulation on levels of inflammatory factors and neurotransmitters.

    参考文献
    相似文献
    引证文献
引用本文

陈艳,戴数.舒肝解郁胶囊联合文拉法辛治疗抑郁症临床研究[J].新中医,2021,53(18):59-62

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-09-24
  • 出版日期:
文章二维码